Dual-Action CAR-T Therapy Shows Promise in Blood Cancer

Researchers in Ribeirão Preto, Brazil, have engineered immune cells with a dual mechanism to attack tumors and resist immune suppression, a potential advance in cancer immunotherapy. The findings are preliminary and not yet peer-reviewed or clinically validated. This matters as it could improve treatment efficacy for blood cancers if confirmed in further studies.